Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Escitalopram Oxalate

FDA-approved product (tablet, oral), marketed as Escitalopram, Escitalopram Oxalate, Lexapro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Escitalopram Oxalate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Depressive disorder
  • Generalized anxiety disorder
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Escitalopram Oxalate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Escitalopram Oxalate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.

    NCT07645807 · start 2026-06-11

    Registered record
    Registry ID
    NCT07645807
    Conditions
    Adjunct in the Treatment of Depressive Disorder
    Interventions
    1. Escitalopram (as escitalopram oxalate) tablet 2. CreNeuroSTM CNS Fish Oil Plus Softgels; 1. Escitalopram (as escitalopram oxalate) tablet 2. Placebo softgels
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-06-11
    Completion
    2027-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdjunct in the Treatment of Depressive Disorder
    Intervention1. Escitalopram (as escitalopram oxalate) tablet 2. CreNeuroSTM CNS Fish Oil Plus Softgels; 1. Escitalopram (as escitalopram oxalate) tablet 2. Placebo softgels
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Atorvastatin Plus Escitalopram for Depression With Dyslipidemia

    NCT07712367 · start 2025-09-01

    Registered record
    Registry ID
    NCT07712367
    Conditions
    Depressive Episode, Dyslipidemia
    Interventions
    Escitalopram plus atorvastatin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-09-01
    Completion
    2026-05-27
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Episode, Dyslipidemia
    InterventionEscitalopram plus atorvastatin
    PhaseNot recorded
    Registry statusCompleted

  • Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD

    NCT06828887 · start 2025-04-03

    Registered record
    Registry ID
    NCT06828887
    Conditions
    MDD
    Interventions
    LV232 40mg; LV232 60mg; Escitalopram; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-04-03
    Completion
    2026-12-20
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMDD
    InterventionLV232 40mg; LV232 60mg; Escitalopram; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET

    NCT06476509 · start 2024-05-30

    Registered record
    Registry ID
    NCT06476509
    Conditions
    Major Depressive Disorder
    Interventions
    LV232 40mg; Escitalopram 20 mg; LV232 60mg; LV232 20mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-05-30
    Completion
    2025-05-23
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionLV232 40mg; Escitalopram 20 mg; LV232 60mg; LV232 20mg
    PhasePhase 1
    Registry statusCompleted

  • A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

    NCT06049797 · start 2023-11-15

    Registered record
    Registry ID
    NCT06049797
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Paroxetine; Citalopram; Escitalopram; Desvenlafaxine; Venlafaxine; Gabapentin; Clonidine; Pregabalin; Oxybutynin; Any other SSRI/SNRI not already specified; Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-11-15
    Completion
    2026-05-07
    Enrolment
    999

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Paroxetine; Citalopram; Escitalopram +8 more
    PhaseNot recorded
    Registry statusCompleted

  • Development and Application of Comprehensive Intervention Techniques for Adolescent Depression

    NCT05945342 · start 2023-01-31

    Registered record
    Registry ID
    NCT05945342
    Conditions
    Depressive Disorder; Adolescent
    Interventions
    Escitalopram; Interpersonal Psychotherapy for Adolescent; Escitalopram combined with psychotherapy; Escitalopram combined with rTMS; Escitalopram combined with sham rTMS
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-01-31
    Completion
    2025-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder; Adolescent
    InterventionEscitalopram; Interpersonal Psychotherapy for Adolescent; Escitalopram combined with psychotherapy; Escitalopram combined with rTMS +1 more
    PhaseNot applicable
    Registry statusUnknown

  • Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder

    NCT05952713 · start 2022-10-01

    Registered record
    Registry ID
    NCT05952713
    Conditions
    Major Depressive Disorder
    Interventions
    Antidepressant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2023-07-01
    Enrolment
    73,336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionAntidepressant
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

    NCT04951609 · start 2021-09-02

    Registered record
    Registry ID
    NCT04951609
    Conditions
    Depressive Disorder, Major
    Interventions
    Seltorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-09-02
    Completion
    2024-04-08
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Major
    InterventionSeltorexant; Placebo
    PhasePhase 1
    Registry statusTerminated

  • A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

    NCT04965272 · start 2021-08-18

    Registered record
    Registry ID
    NCT04965272
    Conditions
    Generalized Anxiety Disorder
    Interventions
    Cariprazine 0.75 mg/day; Cariprazine 1.5 mg/day; Cariprazine 3.0 mg/day; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2021-08-18
    Completion
    2021-08-24
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    InterventionCariprazine 0.75 mg/day; Cariprazine 1.5 mg/day; Cariprazine 3.0 mg/day; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment

    NCT05145270 · start 2019-11-30

    Registered record
    Registry ID
    NCT05145270
    Conditions
    Major Depressive Disorder
    Interventions
    Escitalopram+Sulforaphane; Escitalopram+rTMS; Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-11-30
    Completion
    2022-11-30
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionEscitalopram+Sulforaphane; Escitalopram+rTMS; Escitalopram
    PhasePhase 4
    Registry statusUnknown

  • Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

    NCT03993457 · start 2019-07-23

    Registered record
    Registry ID
    NCT03993457
    Conditions
    Depression
    Interventions
    Escitalopram; Bupropion
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-07-23
    Completion
    2022-03-25
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionEscitalopram; Bupropion
    PhasePhase 4
    Registry statusTerminated

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting

  • Anxiety and Depression in Epilepsy: A Treatment Study

    NCT03464383 · start 2018-05-07

    Registered record
    Registry ID
    NCT03464383
    Conditions
    Anxiety; Depression; Epilepsy
    Interventions
    Escitalopram 10mg; Referral to Psychiatry; Survey only
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-05-07
    Completion
    2019-09-20
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety; Depression; Epilepsy
    InterventionEscitalopram 10mg; Referral to Psychiatry; Survey only
    PhasePhase 4
    Registry statusCompleted

  • Cortical Ischemic Stroke and Serotonin

    NCT02865642 · start 2016-08

    Registered record
    Registry ID
    NCT02865642
    Conditions
    Stroke
    Interventions
    Serotonin Uptake Inhibitors; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-08
    Completion
    2020-12
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke
    InterventionSerotonin Uptake Inhibitors; Placebo
    PhasePhase 2
    Registry statusUnknown

  • The ISLAND Study: InSuLa Assessed Needs for Depression

    NCT02137369 · start 2014-09

    Registered record
    Registry ID
    NCT02137369
    Conditions
    Depression
    Interventions
    Selective serotonin re-uptake inhibitor; Cognitive Behavioral Therapy; Combination treatment (SSRI + CBT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-09
    Completion
    2019-10-24
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionSelective serotonin re-uptake inhibitor; Cognitive Behavioral Therapy; Combination treatment (SSRI + CBT)
    PhasePhase 4
    Registry statusCompleted